GILD

Business Context and Reporting Period

This Form 10-Q covers Gilead Sciences, Inc. for the three and nine months ended September 30, 1998. Gilead is a biopharmaceutical company focused on research and development, with its primary commercial product being VISTIDE (cidofovir injection) for the treatment of CMV retinitis in AIDS patients. The company has incurred losses in every quarter since its inception, with an accumulated deficit of approximately $202.3 million as of September 30, 1998.

Key Financial Metrics

Revenue Breakdown (9 Months 1998): Contract revenues ($17.3 million), Product sales ($4.8 million), and Royalty revenues ($1.5 million).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 21.6% for the nine-month period compared to 1997. This was driven by a drop in contract revenues (excluding a $10.0 million milestone payment from Pharmacia & Upjohn in 1997) and lower net product sales due to declining incidence of CMV retinitis.
• Increased Expenses: Research and Development (R&D) expenses rose 38.0% to $54.0 million, and Selling, General, and Administrative (SG&A) expenses increased 24.5% to $23.1 million. These increases reflect the advancement of four therapeutic drug candidates into later clinical stages and expanded staffing.
• Widened Loss: The net loss more than doubled for the nine-month period, increasing from $15.6 million in 1997 to $39.8 million in 1998.
• Liquidity: Cash and short-term investments decreased by approximately $26.4 million from year-end 1997, primarily due to net cash used in operations and capital expenditures, partially offset by proceeds from stock issuances.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur losses throughout 1998 and 1999. R&D and SG&A expenses are projected to increase significantly for the remainder of 1998 and throughout 1999 to support clinical trials and the potential launch of PREVEON (adefovir dipivoxil) for HIV treatment.
• Capital Resources: The company believes existing capital resources, supplemented by revenues, are adequate for the foreseeable future. However, future funding may be required via equity, debt, or collaborations.
• Year 2000 Compliance: Gilead is implementing a project to ensure software and hardware compliance. Estimated external costs are approximately $2 million, with $0.5 million incurred to date. The company anticipates completion by the second quarter of 1999.
• Risks: Key risks include the failure of product candidates in clinical trials, regulatory delays, intense competition, pricing pressures, and uncertainties regarding the market size for VISTIDE. There is also risk associated with third-party suppliers failing to achieve Year 2000 compliance.

Investor Verification Checklist

• Verify the sustainability of contract revenues, specifically the $15.5 million reimbursement from Roche for GS 4104 development, as this significantly impacts the current period's revenue profile.
• Monitor the burn rate of cash given the $30.4 million operating cash outflow and the expectation of increased R&D spending in 1999.
• Assess the progress of the four therapeutic drug candidates moving into later clinical stages to validate the justification for rising R&D expenses.
• Review the status of Year 2000 compliance for critical third-party suppliers, particularly financial institutions and contract manufacturers, as noted in the risk factors.
• Confirm the timeline and regulatory status for the potential launch of PREVEON, which is cited as a driver for future SG&A expansion.